“The NCSI Study demonstrates the benefit of following a protocolized approach to AMICS, which includes early implantation of Impella. We are impressed with the improved survival rates seen with the use of best practices compared to the stagnant historical survival rate,” said Dr. Basir. “It is important to emphasize that the majority of hospitals in the NCSI Study were large community-based programs where heart attack patients first present. Giving these care teams a safe and effective protocol to manage critically ill patients has saved many lives.”
“NCSI is the largest prospective study of therapy for AMICS done in the U.S. in the last 20 years. We have found that the original observations from the Detroit Cardiogenic Shock Initiative have been reproduced showing significantly higher survival rates,” said William O’Neill, MD, medical director of the Henry Ford Health System Center for Structural Heart Disease and co-principal investigator of the study. “If implemen
Press release content from Business Wire. The AP news staff was not involved in its creation.
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
April 21, 2021 GMT
KIRKLAND, Wash. (BUSINESS WIRE) Apr 21, 2021
Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are now available and can be ordered through your physician.
Atlas Genomics is a CLIA-certified, high complexity diagnostic lab providing the highest quality of testing, service, and technology. Prevencio’s and Atlas’ partnership incorporates the use of Microsoft’s Azure AI-computing cloud for HART algorithm processing, scoring, report generation and secure physician delivery of Prevencio’s HART test reports. Additional terms of the deal are not disclosed.
25
Tenax Therapeutics, Inc. (NASDAQ: TENX)announced positive data from its Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction. Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial was published in the Journal of American College of Cardiology: Heart Failure.
The publication had a 84% responder rate during the open label phase as 37 or 44 patients met responder criteria and were randomized to levosimendan (n=18) or placebo (n=19). Levosimendan did not significantly reduce the primary endpoint of exercise-PCWP but has reduced PCWP measured across all exercise stages. The 6 week study design utilized invasive cardiovascular hemodynamics and secondary clinical endpoints that include a 6 minute walk test.
Hypertensive Disorders of Pregnancy Up Early Maternal Mortality medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Heart failure impacts more than 6.5 million people in the U.S. As a progressive disease, it worsens over time, leading to a reduced quality of life, greater risk of complications and death. CRT is an established treatment for select patients with heart failure and has been demonstrated to improve survival and quality of life and reduce heart failure-related hospitalizations. It is commonly stated within the cardiology community that about a third of patients do not respond to CRT, said Michael R. Gold, M.D., Ph.D., Michael E. Assey Professor of Medicine at the Medical University of South Carolina, Charleston. However, REVERSE shows that with mild heart failure, patient stability is a long-term benefit of CRT, similar to patient improvement. Our current classifications do not give us the full picture of how patients benefit from CRT. We need to redefine our current understanding of CRT response to include stability as a favorable outcome for this patient population.